Stimulant Abuser Groups to Engage in 12-Step

Phase 3

Completed

• Conditions: Drug Abuse

• Registration Number: NCT00573183
• Lead Sponsor: University of Washington

Brief Summary

The purpose of this study is to determine whether a combined group and individual 12-Step facilitative (TSF) intervention, Stimulant Abuser Groups to Engage in 12 -Step (STAGE-12), improves substance -related outcomes.

Detailed Description

This protocol is to evaluate the degree to which a combined group and individual 12-Step facilitative (TSF) intervention, Stimulant Abuser Groups to Engage in 12 -Step (STAGE-12), improves substance -related outcomes compared to treatment as usual (TAU) without STAGE-12 among stimulant abusers. The primary objective is to evaluate reduction in percent of days of stimulant use as measured by self-report. Secondary objectives include evaluating reduction in percent days of use of other substances, the degree to which STAGE-12 increases involvement in 12-step activities and attendance at 12-step meetings, and the extent to which such 12 -step involvement and meeting attendance mediate substance use outcomes.

Study Timeline

• Study First Submitted: 2007-12-13
• Study First Submitted QC: 2007-12-13
• Study First Posted: 2007-12-14
• Study Start: 2008-01
• Primary Completion: 2010-04
• Study Completion: 2010-04
• Results First Submitted: 2013-06-04
• Results First Submitted QC: 2013-12-09
• Results First Posted: 2014-01-29
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-24
• Last Update Posted: 2016-12-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 471

Inclusion Criteria

• seeking outpatient treatment for stimulant abuse or dependence
• current diagnosis of stimulant abuse or dependence
• willing to participate in the protocol

Exclusion Criteria

• not sufficiently medically or psychiatrically stable
• pending legal action that would inhibit their participation in the study
• in need of detoxification from opiates

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Days of Stimulant Use	6 months	Number of days of use of stimulant drugs within 30-day blocks across a 6-month post-baseline period

Secondary Outcome Measures

Name	Time	Method
Attendance at 12-step Meetings	6 months	Days of attendance at 12-step meetings within 30-day blocks across a 6-month post-baseline period

Trial Locations

Locations (10)

Gateway Community Services; 🇺🇸 Jacksonville, Florida, United States

Hina Mauka Kaneohe Rehabilitation Services; 🇺🇸 Kaneohe, Hawaii, United States

Maryhaven, Inc.; 🇺🇸 Columbus, Ohio, United States

Willamette Family Treatment Services; 🇺🇸 Eugene, Oregon, United States

ChangePoint, Inc.; 🇺🇸 Portland, Oregon, United States

Addiction Medicine Services (WPIC); 🇺🇸 Pittsburgh, Pennsylvania, United States

Dorchester Alcohol and Drug Commission; 🇺🇸 Summerville, South Carolina, United States

Nexus Recovery Center; 🇺🇸 Dallas, Texas, United States

Evergreen Manor, Inc.; 🇺🇸 Everett, Washington, United States

Recovery Centers of King County; 🇺🇸 Seattle, Washington, United States